Phase III
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
Pfizer’s Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.
May has been fruitful for research into the prevention and diagnosis of Alzheimer’s disease, the mechanisms behind early symptoms and potential treatments.
Despite a growing product revenue, Beigene reported a net loss of $434.4 million for the first quarter of 2022, as well as updates to its audit from the SEC.
The FDA has extended the review period for Myfembree, following the supplemental New Drug Application from Pfizer and Myovant. Here’s more about this news.
With a robust pipeline, Vertex is moving beyond its market dominance in cystic fibrosis and laying claim to multiple markets in diabetes, pain, kidney disease and sickle cell disease.
A post hoc analysis of data from the Phase II CENTAUR study showed a 10.6-month longer median survival duration for AMX0035 participants, Amylyx announced Thursday.
Novartis announced on Thursday that it will be temporarily and voluntarily suspending the production of its cancer therapeutics Lutathera and Pluvicto at facilities in Italy and New Jersey.
AstraZeneca and Daiichi Sankyo’s breast cancer therapeutic Enhertu received supplemental approval for an earlier form of breast cancer from the U.S. Food and Drug Administration.
Two biologic therapeutic candidates have met their primary endpoints in phase III trials, including AstraZeneca’s Champion-NMOSD trial and Argenx’s Advance trial.
PRESS RELEASES